“The place of adalimumab in the treatment pathway is still under discussion,” Denniston says. “It is clearly effective and well tolerated. Most uveitis experts seem to use it after the failure of one or more ‘second line’ immunosuppressants, such as mycophenolate mofetil or cyclosporine, but practice is quite variable and will also depend on local availability of the drug.”
“It will be very interesting to see how this will be affected by the recent licensing by the FDA and the EMA of adalimumab for adult noninfectious intermediate, posterior, and panuveitis,” he adds.
AbbVie funded the trial, employed five of the 16 authors, and had various relationships with nine other authors, including Dr. Nguyen.